SELENTUS DEVELOPS MEDICAL DEVICES FOR SURGICAL BLEEDING AND WOUND THERAPY

Approved for sale in Europe

Haemostatic absorbable gelatine sponge with surface modification for increased tissue adhesion

PATENTS GRANTED IN U.K.

AND U.S.A AND PENDING 

WORLDWIDE

Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus' lead product, TenaTac®, was approved for sale in Europe in September 2019 and is licensed to CuraMedrix B.V. in Europe and selected ROW territories.

Now

Available

For Vets!

Please click below to request further information on territories available for partnership, or to purchase TenaTac® in Europe:  

This website is intended for healthcare professionals. TenaTac® is approved for use in Europe. TenaTac® is not approved for use in the USA.

© 2019 Selentus Science Limited.

United Kingdom

TenaTac® is a registered trade mark of Selentus Science Ltd.